CERo Therapeutics

Latest clinical program signals indexed for CERo Therapeutics.

1. IFCT-2003 — Phase 2

   Jun 8, 2026
   Clinical update →

2. IFCT-1904 — Phase 2

   Jun 8, 2026
   Clinical update →

3. FFCD 2006 NEORAF — Phase 2

   Jun 8, 2026
   Clinical update →

4. Fianlimab for Pleural mesothelioma — Phase 2

   Jun 8, 2026
   Clinical update →

5. Cyramza /ml concentrate for stomach cancer stage IV with me… — Phase 2

   Jun 8, 2026
   Clinical update →

6. PRODIGE85-KANALRAD — Phase 3

   Jun 8, 2026
   Clinical update →

7. IFCT-2101 — Phase 2

   Jun 8, 2026
   Clinical update →

8. ICO-2020-01 REPAIR — Phase 2

   Jun 8, 2026
   Clinical update →

1. 2022-502642-27-00

   ICO-2020-01 REPAIR

   Phase 2 · active · other

   RElapse in previously irradiated Prostate bed

   CTIS ↗
2. 2023-505972-32-00

   PRODIGE85-KANALRAD

   Phase 3 · active · small_molecule

   locally advanced anal squamous cell carcinoma

   CTIS ↗
3. 2023-508473-86-00

   ICO-2023-25 OPTIMISE

   Phase 1 · active · other

   metastatic prostate cancer

   CTIS ↗
4. 2023-509729-33-00

   PERSEVERANCE EU

   Phase 1 · active · other

   Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

   CTIS ↗
5. 2023-510387-13-00

   IFCT-2101

   Phase 2 · active · small_molecule

   advanced ALK-positive non-small cell lung cancer

   CTIS ↗
6. 2024-510893-25-00

   BRADI ICO-2023-15

   Phase 3 · active · small_molecule

   Brain metastases of cancer > brain radionecrosis

   CTIS ↗
7. 2024-511185-37-00

   EC-120888

   Approved · active · small_molecule

   Completely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)

   CTIS ↗
8. 2024-512028-12-00

   IFCT-2003

   Phase 2 · active · small_molecule

   Advanced ROS1-positive non-small cell lung cancer

   CTIS ↗
9. 2024-512855-19-00

   TEP-64Cu-ATSM-Rectum

   Phase 2 · active · other

   Rectal adenocarcinoma

   CTIS ↗
10. 2024-513207-13-00

    IMFINZI 50 mg/mL concentrate for solution for infusion.

    Phase 2 · active · small_molecule

    oligometastatic hormone sensitive prostate cancer

    CTIS ↗
11. 2024-513248-27-00

    ZOSTER ICO-N-2018-14

    Phase 3 · active · small_molecule

    Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy

    CTIS ↗
12. 2024-513515-27-00

    Cyramza /ml concentrate for stomach cancer stage IV with me…

    Phase 2 · active · small_molecule

    stomach cancer stage IV with metastases

    CTIS ↗
13. 2024-514030-20-00

    ENGIC 01-COLOSOTO

    Phase 2 · active · small_molecule

    colorectal cancer

    CTIS ↗
14. 2024-514057-30-00

    ICO-2023-16

    Phase 1 · active · other

    cell lung carcinoma

    CTIS ↗
15. 2024-514078-29-00

    ICO-2023-10

    Phase 2 · active · small_molecule

    gastric and gastro-oesophageal junction adenocarcinomas

    CTIS ↗
16. 2024-514107-34-00

    FFCD 2006 NEORAF

    Phase 2 · active · small_molecule

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    CTIS ↗
17. 2024-514560-10-00

    ICO-2023-14

    Phase 2 · active · small_molecule

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    CTIS ↗
18. 2024-514586-20-01

    IFCT-1701

    Phase 3 · active · small_molecule

    Non small cell lung cancer

    CTIS ↗
19. 2024-515221-29-00

    PRODIGE 51 - GASTFOX

    Phase 3 · active · small_molecule

    Locally advanced or metastatic oesogastric adenocarcinoma

    CTIS ↗
20. 2024-515788-73-00

    FFCD1703

    Phase 2 · active · small_molecule

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    CTIS ↗
21. 2024-515850-26-00

    Dopacis 90 MBq/ml oplossing voor injectie

    Phase 2 · active · small_molecule

    patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI

    CTIS ↗
22. 2024-515943-44-00

    IMFINZI 50 mg/mL concentrate for solution for infusion.

    Phase 2 · active · small_molecule

    Non small cell lung cancer, Poor general status

    CTIS ↗
23. 2024-515944-22-00

    IFCT-1904

    Phase 2 · active · small_molecule

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    CTIS ↗
24. 2024-515945-40-00

    IFCT-2103

    Phase 3 · active · small_molecule

    Non small cell lung cancer

    CTIS ↗
25. 2024-515946-17-00

    IFCT-1805

    Phase 3 · active · small_molecule

    Non Small Cell Lung Cancer

    CTIS ↗
26. 2024-515948-23-00

    GCO-003 TARLANEC

    Phase 3 · active · small_molecule

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    CTIS ↗
27. 2024-516282-37-00

    ICO-N-2013-03

    Phase 2 · active · small_molecule

    Breast cancer

    CTIS ↗
28. 2024-517204-11-00

    FFCD 1709 - SIRTCI

    Phase 2 · active · small_molecule

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    CTIS ↗
29. 2024-517316-29-00

    IFCT-2401 SPORADIC

    Phase 2 · active · small_molecule

    Unresectable stage III Non-Small Cell Lung Cancer

    CTIS ↗
30. 2024-517362-41-00

    Prodige 54 SAMCO

    Phase 2 · active · small_molecule

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    CTIS ↗
31. 2024-517658-90-00

    [68Ga]Ga-PentixaFor

    Phase 1 · active · small_molecule

    triple-negative breast cancer

    CTIS ↗
32. 2024-517856-36-00

    MEDI4736 Placebo, DURVALUMAB

    Phase 3 · active · small_molecule

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    CTIS ↗
33. 2024-518143-38-00

    FUNGEMAX

    Phase 3 · active · small_molecule

    Metastatic pancreatic cancer

    CTIS ↗
34. 2024-518553-41-00

    PRODIGE 49 -OSCAR

    Phase 3 · active · small_molecule

    colon cancer and rectal with liver metastasis

    CTIS ↗
35. 2024-518740-20-00

    FFCD 1605 OPTIPRIME

    Phase 2 · active · small_molecule

    metastatic colorectal adenocarcinoma

    CTIS ↗
36. 2024-518741-21-00

    PRODIGE 34 - ADAGE

    Phase 2 · active · small_molecule

    colon cancer

    CTIS ↗
37. 2024-519052-82-00

    ivonescimab

    Phase 2 · active · small_molecule

    pleural mesothelioma

    CTIS ↗
38. 2024-519208-29-00

    Fianlimab for Pleural mesothelioma

    Phase 2 · active · small_molecule

    Pleural mesothelioma

    CTIS ↗
39. 2024-519258-35-00

    PRODIGE 111

    Phase 2 · active · small_molecule

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    CTIS ↗
40. 2024-519753-11-00

    PRODIGE 104 A

    Phase 2 · active · small_molecule

    Resectable borderline pancreatic adenocarcinoma

    CTIS ↗
41. 2024-519971-25-00

    NIVOLUMAB for Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    Phase 3 · active · small_molecule

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    CTIS ↗
42. 2025-521302-17-00

    PRODIGE 118-PEHRICCA

    Phase 3 · active · small_molecule

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    CTIS ↗
43. 2025-522108-26-00

    FRUZAQLA hard capsules for métastatique colorectal cancer

    Phase 2 · active · small_molecule

    métastatique colorectal cancer

    CTIS ↗
44. 2025-522395-92-00

    ENGIC 06 FRUQUITAS

    Phase 3 · active · small_molecule

    metastatic oeso-gastric adenocarcinoma

    CTIS ↗
45. 2025-522790-10-00

    IFCT-2502

    Phase 2 · active · small_molecule

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    CTIS ↗
46. 2025-524675-23-00

    IDEA

    Approved · active · small_molecule

    Ulcerative Colitis

    CTIS ↗
47. NCT06834282

    CER-1236

    Phase 1 · active · small_molecule

    AML

    CT.gov ↗